Genetic makeup of large granular lymphocytic (LGL) leukemia
Genomic Architecture of LGL Leukemia
['FUNDING_R01'] · UNIVERSITY OF VIRGINIA · NIH-11169868
This project looks at the gene changes and molecular signals behind LGL leukemia to guide future, more precise treatments for people with the disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF VIRGINIA (nih funded) |
| Locations | 1 site (CHARLOTTESVILLE, UNITED STATES) |
| Trial ID | NIH-11169868 on ClinicalTrials.gov |
What this research studies
If I join, researchers will examine the genes and molecular features in my blood and bone marrow cells and compare them to healthy donors. They will study common mutations—especially in STAT3 and in genes that control DNA methylation—and use cell models to see how those changes affect cell growth, signaling, and inflammatory signals. Tests will include gene expression, chromatin accessibility, DNA methylation, cytokine profiling, and growth and signaling assays in lab-grown cells and primary samples. The team aims to connect specific genetic and epigenetic changes to disease behavior and point to molecular targets for future therapies.
Who could benefit from this research
Good fit: Ideal candidates are people diagnosed with large granular lymphocytic leukemia who can provide blood or marrow samples and share clinical information.
Not a fit: People without LGL leukemia or with unrelated blood disorders are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could help identify molecular targets that lead to more effective, less broadly immunosuppressive treatments for people with LGL leukemia.
How similar studies have performed: Previous studies have already found recurrent STAT3 mutations and epigenetic changes in LGL leukemia, but turning those findings into targeted therapies remains largely unproven.
Where this research is happening
CHARLOTTESVILLE, UNITED STATES
- UNIVERSITY OF VIRGINIA — CHARLOTTESVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LOUGHRAN, THOMAS P. — UNIVERSITY OF VIRGINIA
- Study coordinator: LOUGHRAN, THOMAS P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus